Information Provided By: 
Fly News Breaks for February 22, 2018
GMED
Feb 22, 2018 | 08:07 EDT
Canaccord analyst Kyle Rose raised his price target on Globus Medical to $53 from $47 following solid Q4 results. The analyst cited continued share gains in the U.S. business, strong growth outside the U.S., and positive momentum in its Emerging Technologies segment. Rose reiterated his Buy rating on Globus Medical shares.
News For GMED From the Last 2 Days
There are no results for your query GMED
